{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:04:25Z","timestamp":1789049065012,"version":"build-2803163510"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.blre.2026.101364","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T23:34:46Z","timestamp":1771716886000},"page":"101364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Revisiting antiphospholipid syndrome: A thrombo-inflammatory disorder beyond clotting"],"prefix":"10.1016","volume":"76","author":[{"given":"Catherine B.","family":"Ducker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan V","family":"Preece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Pericleous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Laffan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa J.","family":"Arachchillage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2026.101364_bb0005","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1160\/TH04-12-0839","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","volume":"93","author":"Pengo","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0010","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2026.101364_bb0015","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.blre.2026.101364_bb0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41569-022-00770-1","article-title":"Vascular endothelial cell development and diversity","volume":"20","author":"Trimm","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.blre.2026.101364_bb0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12884-025-07471-w","article-title":"Antiphospholipid syndrome in pregnancy: a comprehensive literature review","volume":"25","author":"Murvai","year":"2025","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.blre.2026.101364_bb0030","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.blre.2026.101364_bb0035","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1161\/01.CIR.103.13.1718","article-title":"Inflammation and thrombosis","volume":"103","author":"Libby","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2026.101364_bb0040","article-title":"Sepsis-induced coagulopathy: an update on pathophysiology, biomarkers, and current guidelines","volume":"13","author":"Tsantes","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.blre.2026.101364_bb0045","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.21873\/invivo.12991","article-title":"Thromboinflammation in sepsis and heparin: a review of literature and pathophysiology","volume":"36","author":"Vagionas","year":"2022","journal-title":"In Vivo"},{"key":"10.1016\/j.blre.2026.101364_bb0050","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/bloodadvances.2020002888","article-title":"Platelets as drivers of ischemia\/reperfusion injury after stroke","volume":"5","author":"Shaik","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101364_bb0055","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41586-024-07873-4","article-title":"Fibrin drives thromboinflammation and neuropathology in COVID-19","volume":"633","author":"Ryu","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101364_bb0060","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3324\/haematol.2019.239343","article-title":"Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance","volume":"105","author":"Conran","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101364_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1676578","article-title":"A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry","volume":"16","author":"Pine","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101364_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152707","article-title":"Molecular mechanisms underlying thrombosis in systemic lupus erythematosus \u2013 a systematic review","volume":"72","author":"Larsen","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.blre.2026.101364_bb0075","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1160\/TH13-06-0509","article-title":"Anti-prothrombin (aPT) and anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review","volume":"111","author":"Sciascia","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0080","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11239-021-02458-8","article-title":"Roles of factor Xa beyond coagulation","volume":"52","author":"Ruf","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.blre.2026.101364_bb0085","doi-asserted-by":"crossref","first-page":"7192","DOI":"10.4049\/jimmunol.167.12.7192","article-title":"Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin","volume":"167","author":"Hwang","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2026.101364_bb0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2022-166074","article-title":"Anticoagulation practice, recurrent thrombosis, and major bleeding in antiphospholipid syndrome- a multicentre observational study in the United Kingdom","volume":"140","author":"Crossette-Thambiah","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0100","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0105","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101364_bb0110","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2026.101364_bb0115","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101364_bb0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs Vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2026.101364_bb0125","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/369084","article-title":"Determining risk factors of bleeding in patients on warfarin treatment","volume":"2014","author":"Uygung\u00fcl","year":"2014","journal-title":"Adv Hematol"},{"key":"10.1016\/j.blre.2026.101364_bb0130","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0961203314536479","article-title":"Toll-like receptor 4 and \u03b22 glycoprotein I interaction on endothelial cells","volume":"23","author":"Borghi","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.blre.2026.101364_bb0135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bjh.14632","article-title":"Pathogenesis and management of antiphospholipid syndrome","volume":"178","author":"Arachchillage","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101364_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100202","article-title":"Antiphospholipid antibodies induce proinflammatory and procoagulant pathways in endothelial cells","volume":"6","author":"Patsouras","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.blre.2026.101364_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2017.01124","article-title":"Reduction of endothelial nitric oxide increases the adhesiveness of constitutive endothelial membrane ICAM-1 through Src-mediated phosphorylation","volume":"8","author":"Gao","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.blre.2026.101364_bb0150","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ccc.2019.12.009","article-title":"Nitric oxide and endothelial dysfunction","volume":"36","author":"Cyr","year":"2020","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.blre.2026.101364_bb0155","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/intimm\/dxh229","article-title":"Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome","volume":"17","author":"Simoncini","year":"2005","journal-title":"Int Immunol"},{"key":"10.1016\/j.blre.2026.101364_bb0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.atherosclerosissup.2017.05.039","article-title":"Serum of patients with antiphospholipid syndrome induces adhesion molecules in endothelial cells","volume":"30","author":"Engel","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.blre.2026.101364_bb0165","article-title":"Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome","author":"Dignat-George","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0170","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1160\/TH12-05-0346","article-title":"Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome","volume":"109","author":"Pericleous","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0175","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/rai2.12072","article-title":"Role of \u03b22-glycoprotein I in the pathogenesis of the antiphospholipid syndrome","volume":"3","author":"Li","year":"2023","journal-title":"Rheumatol Autoimmunity"},{"key":"10.1016\/j.blre.2026.101364_bb0180","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.thromres.2004.06.015","article-title":"\u03b22-Glycoprotein I and LDL-receptor family members","volume":"114","author":"de Groot","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2026.101364_bb0185","author":"Lauder"},{"key":"10.1016\/j.blre.2026.101364_bb0190","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1074\/jbc.M008224200","article-title":"Dimers of \u03b22-Glycoprotein I Mimic thein Vitro Effects of \u03b22-Glycoprotein I-Anti-\u03b22-glycoprotein I antibody complexes","volume":"276","author":"Lutters","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2026.101364_bb0195","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood-2017-11-814681","article-title":"Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium","volume":"131","author":"Sacharidou","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0200","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/35006683","article-title":"Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex","volume":"404","author":"Fuentes-Prior","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101364_bb0205","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood.V79.3.837.837","article-title":"Increase in plasma thrombomodulin in lupus erythematosus with antiphospholipid antibodies","volume":"79","author":"Karmochkine","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0210","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/jth.12722","article-title":"Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome","volume":"12","author":"Arachchillage","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0215","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/jalm\/jfaa072","article-title":"Anti-domain I \u03b22-glycoprotein I antibodies and activated protein C resistance predict thrombosis in antiphospholipid syndrome: TAC(I)T study","volume":"5","author":"Zuily","year":"2020","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.blre.2026.101364_bb0220","first-page":"442","article-title":"Regulation of growth and remodeling of blood vessels: the unique role of urokinase","volume":"95","author":"Parfenova","year":"2009","journal-title":"Ross Fiziol Zh Im I M Sechenova"},{"key":"10.1016\/j.blre.2026.101364_bb0225","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1083\/jcb.105.6.2535","article-title":"Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells","volume":"105","author":"Pepper","year":"1987","journal-title":"J Cell Biol"},{"key":"10.1016\/j.blre.2026.101364_bb0230","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1055\/s-0038-1646310","article-title":"Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders","volume":"68","author":"Jurado","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0235","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1055\/s-0038-1650552","article-title":"Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies--a crucial role for acquired free protein S deficiency","volume":"76","author":"Ames","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0240","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.thromres.2017.06.028","article-title":"Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS)","volume":"158","author":"Grosso","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2026.101364_bb0245","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1055\/s-0039-1692428","article-title":"Antiphospholipid syndrome in chronic thromboembolic pulmonary hypertension: a well-defined subgroup of patients","volume":"119","author":"Jiang","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0250","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/keg273","article-title":"Tissue factor in antiphospholipid syndrome: shifting the focus from coagulation to endothelium","volume":"42","author":"Amengual","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.blre.2026.101364_bb0255","article-title":"Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101364_bb0260","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10237-023-01803-5","article-title":"Numerical study of ultra-large von Willebrand factor multimers in coagulopathy","volume":"23","author":"Rahmati","year":"2024","journal-title":"Biomech Model Mechanobiol"},{"key":"10.1016\/j.blre.2026.101364_bb0265","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1073\/pnas.0608422104","article-title":"Shear-induced unfolding triggers adhesion of von Willebrand factor fibers","volume":"104","author":"Schneider","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.blre.2026.101364_bb0270","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1161\/ATVBAHA.116.307660","article-title":"Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation","volume":"36","author":"Dhanesha","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2026.101364_bb0275","doi-asserted-by":"crossref","first-page":"1361519","DOI":"10.3389\/fimmu.2024.1361519","article-title":"Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome","volume":"15","author":"Feng","year":"2024","journal-title":"Front Immunol"},{"issue":"suppl 9","key":"10.1016\/j.blre.2026.101364_bb0280","article-title":"Cytokine profiles in antiphospholipid syndrome [abstract]","volume":"77","author":"Liu","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.blre.2026.101364_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102665","article-title":"A cell-based model to study mechanisms of endothelial-dependent thrombin generation in response to inflammation and its modulation by hydroxychloroquine","volume":"9","author":"Arachchillage","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0290","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101364_bb0295","author":"Chaturvedi"},{"key":"10.1016\/j.blre.2026.101364_bb0300","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J Thrombosis Haemostasis"},{"key":"10.1016\/j.blre.2026.101364_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1459842","article-title":"Cell-bound complement activation products in antiphospholipid antibody-positive patients without other systemic autoimmune rheumatic diseases","volume":"15","author":"Erkan","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101364_bb0310","first-page":"455","article-title":"Antiphospholipid antibodies and complement activation in patients with cerebral ischemia","volume":"10","author":"Davis","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.blre.2026.101364_bb0315","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1016\/S0021-9258(18)81901-9","article-title":"Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface","volume":"264","author":"Hattori","year":"1989","journal-title":"JBC"},{"key":"10.1016\/j.blre.2026.101364_bb0320","article-title":"Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex*","volume":"265","author":"Hamilton","year":"1990","journal-title":"J Biouxxcal Chem"},{"key":"10.1016\/j.blre.2026.101364_bb0325","doi-asserted-by":"crossref","first-page":"14587","DOI":"10.1016\/S0021-9258(18)66911-X","article-title":"On the mechanism by which complement proteins C5b-9 increase platelet prothrombinase activity","volume":"261","author":"Wiedmer","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2026.101364_bb0330","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI117430","article-title":"C5a-induced expression of P-selectin in endothelial cells","volume":"94","author":"Foreman","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101364_bb0335","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1055\/a-1347-5655","article-title":"The complex relationship between c4b-binding protein, warfarin, and antiphospholipid antibodies","volume":"121","author":"Grosso","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0370","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005489","article-title":"Thrombin generation test as a useful tool for improving disease severity stratification in antiphospholipid syndrome","volume":"11","author":"Yelnik","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.blre.2026.101364_bb0340","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2012-02-412080","article-title":"Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway","volume":"120","author":"Krisinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0345","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ebiom.2016.02.011","article-title":"Complement activation in arterial and venous thrombosis is mediated by plasmin","volume":"5","author":"Foley","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.blre.2026.101364_bb0350","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","article-title":"Molecular intercommunication between the complement and coagulation systems","volume":"185","author":"Amara","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2026.101364_bb0355","first-page":"71","article-title":"Interaction between the coagulation and complement system","volume":"632","author":"Amara","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.blre.2026.101364_bb0360","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: a new complement activation pathway","volume":"12","author":"Huber-Lang","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101364_bb0365","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross talk pathways between coagulation and inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.blre.2026.101364_bb0375","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaut.2007.02.013","article-title":"Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?","volume":"28","author":"Cavazzana","year":"2007","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2026.101364_bb0380","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2009.07.004","article-title":"Patients with antiphospholipid syndrome display endothelial perturbation","volume":"34","author":"Cugno","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2026.101364_bb0385","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.blre.2026.101364_bb0390","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/art.39247","article-title":"Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome","volume":"67","author":"Yalavarthi","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2026.101364_bb0395","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.neuropharm.2018.06.001","article-title":"Anti-\u03b22GPI\/\u03b22GPI induces neutrophil extracellular traps formation to promote thrombogenesis via the TLR4\/MyD88\/MAPKs axis activation","volume":"138","author":"Zha","year":"2018","journal-title":"Neuropharmacology"},{"issue":"Pt 2","key":"10.1016\/j.blre.2026.101364_bb0400","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1042\/bj3310623","article-title":"Histones and basic polypeptides activate Ca2+\/cation influx in various cell types","volume":"331","author":"Gamberucci","year":"1998","journal-title":"Biochem J"},{"key":"10.1016\/j.blre.2026.101364_bb0405","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1538-7836.2011.04544.x","article-title":"Neutrophil extracellular traps promote deep vein thrombosis in mice","volume":"10","author":"Brill","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0410","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm.2184","article-title":"Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases","volume":"16","author":"Massberg","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101364_bb0415","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"von Br\u00fchl","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2026.101364_bb0420","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1164\/rccm.201206-1037OC","article-title":"Circulating histones are mediators of trauma-associated lung injury","volume":"187","author":"Abrams","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.blre.2026.101364_bb0425","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.thromres.2015.10.012","article-title":"Extracellular histones induce tissue factor expression in vascular endothelial cells via TLR and activation of NF-\u03baB and AP-1","volume":"137","author":"Yang","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2026.101364_bb0430","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/j.1538-7836.2011.04422.x","article-title":"Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation","volume":"9","author":"Ammollo","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0435","article-title":"Analytical review: neutrophil extracellular traps and antiphospholipid syndrome","volume":"150909","author":"Butt","year":"2025","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.blre.2026.101364_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108598","article-title":"Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy","volume":"220","author":"Mastellos","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2026.101364_bb0445","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1177\/00220345221107602","article-title":"Mechanisms and therapeutic modulation of neutrophil-mediated inflammation","volume":"101","author":"Hajishengallis","year":"2022","journal-title":"J Dent Res"},{"key":"10.1016\/j.blre.2026.101364_bb0450","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1182\/blood.2024025320","article-title":"Platelet activation and signaling in thrombus formation","volume":"146","author":"Swieringa","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112772","article-title":"Platelets and their role in hemostasis and thrombosis-from physiology to pathophysiology and therapeutic implications","volume":"23","author":"Scridon","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2026.101364_bb0460","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/jth.13763","article-title":"Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study","volume":"15","author":"Hisada","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0465","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1055\/s-0038-1642484","article-title":"Anti-glycoprotein Ib\/IX and IIb\/IIIa antibodies in patients with antiphospholipid antibodies","volume":"71","author":"Galli","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0470","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.jtha.2025.02.016","article-title":"Platelet autoantibodies have an impact on the platelet count in patients","volume":"23","author":"Sachs","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0475","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/art.42801","article-title":"Calprotectin impairs platelet survival in patients with primary antiphospholipid syndrome","volume":"76","author":"Hoy","year":"2024","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2026.101364_bb0480","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1182\/blood.2021014966","article-title":"S100A8\/A9 drives the formation of procoagulant platelets through GPIb\u03b1","volume":"140","author":"Colicchia","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0485","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0020-711X(84)90168-X","article-title":"\u03b22-glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles","volume":"16","author":"Wurm","year":"1984","journal-title":"Int J Biochem"},{"key":"10.1016\/j.blre.2026.101364_bb0490","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2005-05-1943","article-title":"Pathogenic anti-\u03b22-glycoprotein I antibodies recognize domain I of \u03b22-glycoprotein I only after a conformational change","volume":"107","author":"de Laat","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0495","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.1074\/jbc.RA120.013939","article-title":"The J-elongated conformation of \u03b22-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome","volume":"295","author":"Ruben","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2026.101364_bb0510","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2009-03-206367","article-title":"\u03b22 Glycoprotein I (\u03b22GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome","volume":"115","author":"Sikara","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0515","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3390\/cells9051211","article-title":"Characterization of plasma-derived small extracellular vesicles indicates ongoing endothelial and platelet activation in patients with thrombotic antiphospholipid syndrome","volume":"9","author":"\u0160tok","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.blre.2026.101364_bb0500","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1002\/art.30633","article-title":"Immune responses against domain I of \u03b2(2)-glycoprotein I are driven by conformational changes: domain I of \u03b2(2)-glycoprotein I harbors a cryptic immunogenic epitope","volume":"63","author":"de Laat","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2026.101364_bb0505","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1182\/blood-2007-07-100008","article-title":"Excessive exposure to anionic surfaces maintains autoantibody response to \u03b22-glycoprotein I in patients with antiphospholipid syndrome","volume":"110","author":"Yamaguchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0520","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2014-02-554980","article-title":"Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS","volume":"124","author":"Proulle","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0525","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1172\/JCI81660","article-title":"Platelet-derived HMGB1 is a critical mediator of thrombosis","volume":"125","author":"Vogel","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101364_bb0530","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fimmu.2019.00460","article-title":"Alarmin HMGB1 and soluble RAGE as new tools to evaluate the risk stratification in patients with the antiphospholipid syndrome","volume":"10","author":"Manganelli","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101364_bb0535","first-page":"L342","article-title":"HMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor 4","volume":"304","author":"Tadie","year":"2013","journal-title":"Am J Phys Lung Cell Mol Phys"},{"key":"10.1016\/j.blre.2026.101364_bb0540","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1160\/TH08-11-0759","article-title":"High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-\u03baB and Egr-1","volume":"102","author":"Lv","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0545","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bbrc.2016.07.078","article-title":"Platelet-derived high-mobility group box 1 promotes recruitment and suppresses apoptosis of monocytes","volume":"478","author":"Vogel","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.blre.2026.101364_bb0550","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1538-7836.2006.02255.x","article-title":"High-mobility group box 1 protein promotes development of microvascular thrombosis in rats","volume":"5","author":"Ito","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0555","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2016-11-749879","article-title":"Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development","volume":"129","author":"Subramaniam","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0560","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1182\/blood-2012-03-306605","article-title":"Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation","volume":"119","author":"Morrissey","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0565","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2013-07-515726","article-title":"Polyphosphate suppresses complement via the terminal pathway","volume":"123","author":"Wat","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0570","doi-asserted-by":"crossref","first-page":"14587","DOI":"10.1016\/S0021-9258(18)66911-X","article-title":"On the mechanism by which complement proteins C5b-9 increase platelet prothrombinase activity","volume":"261","author":"Wiedmer","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2026.101364_bb0575","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/jth.15320","article-title":"Antiprothrombin antibodies induce platelet activation: A possible explanation for anti-FXa therapy failure in patients with antiphospholipid syndrome?","volume":"19","author":"Chayoua","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0580","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/1358863X16668588","article-title":"Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER\u00ae, RE-COVERTM II, and RE-MEDYTM","volume":"21","author":"Goldhaber","year":"2016","journal-title":"Vasc Med"},{"key":"10.1016\/j.blre.2026.101364_bb0585","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.autrev.2018.04.009","article-title":"Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis","volume":"17","author":"Dufrost","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2026.101364_bb0590","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1055\/s-0040-1705115","article-title":"Antiphosphatidylserine\/Prothrombin Antibodies: An Update on Their Association with Clinical Manifestations of Antiphospholipid Syndrome","volume":"120","author":"Radin","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.754469","article-title":"Anti-phosphatidylserine\/prothrombin antibodies at two points: correlation with lupus anticoagulant and thrombotic risk","volume":"12","author":"Egri","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101364_bb0600","article-title":"Correlation study between lupus anticoagulant and antiphosphatidyl serine\/prothrombin complex along with their clinical significance","author":"Oommen","year":"2025","journal-title":"Apollo Med"},{"key":"10.1016\/j.blre.2026.101364_bb0605","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1373\/clinchem.2004.043414","article-title":"Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism","volume":"51","author":"Nojima","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.blre.2026.101364_bb0840","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1136\/ard.2005.045237","article-title":"Annexin A5 polymorphism (-1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome","volume":"65","author":"de Laat","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2026.101364_bb0615","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood.2023022276","article-title":"Targeting the tissue factor coagulation initiation complex prevents antiphospholipid antibody development","volume":"143","author":"M\u00fcller-Calleja","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0845","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02923.x","article-title":"Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome","volume":"114","author":"Adams","year":"2001","journal-title":"Br J Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2026.101364_bb0610","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jth.12247","article-title":"Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway","volume":"11","author":"Bouwens","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0620","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1055\/s-0038-1649646","article-title":"Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation","volume":"70","author":"Martinuzzo","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0625","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/art.21549","volume":"54","author":"L\u00f3pez-Pedrera","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2026.101364_bb0630","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.molimm.2012.08.012","article-title":"Anti-\u03b22GPI\/\u03b22GPI induced TF and TNF-\u03b1 expression in monocytes involving both TLR4\/MyD88 and TLR4\/TRIF signaling pathways","volume":"53","author":"Xie","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.blre.2026.101364_bb0635","first-page":"371","article-title":"Lipid presentation by the protein C receptor links coagulation with autoimmunity","volume":"1979","author":"M\u00fcller-Calleja","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.blre.2026.101364_bb0640","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1160\/TH14-07-0628","article-title":"Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome","volume":"113","author":"M\u00fcller-Calleja","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0645","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood-2011-01-330639","article-title":"Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells","volume":"118","author":"Prinz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0650","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/bloodadvances.2018017095","article-title":"Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies","volume":"2","author":"M\u00fcller-Calleja","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101364_bb0655","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.2019001530","article-title":"Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis","volume":"134","author":"M\u00fcller-Calleja","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0660","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021331","article-title":"Hydroxychloroquine as an immunomodulatory and antithrombotic treatment in antiphospholipid syndrome","volume":"24","author":"Arachchillage","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2026.101364_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study","volume":"19","author":"Kravvariti","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2026.101364_bb0670","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0961203317716787","article-title":"Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies","volume":"27","author":"Watanabe","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.blre.2026.101364_bb0675","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101364_bb0680","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2026.101364_bb0685","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/ard.2010.135525","article-title":"Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome","volume":"70","author":"L\u00f3pez-Pedrera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2026.101364_bb0690","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2026.101364_bb0695","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00277-005-0028-6","article-title":"Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab--monitoring of antiphospholipid and anti-GP antibodies: a case report","volume":"85","author":"Trappe","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2026.101364_bb0700","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1055\/s-0043-1770784","article-title":"The effect of rituximab on antiphospholipid titers in patients with antiphospholipid syndrome","volume":"7","author":"Youkhana","year":"2023","journal-title":"TH Open"},{"key":"10.1016\/j.blre.2026.101364_bb0705","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.55563\/clinexprheumatol\/cc5taf","article-title":"Rituximab for refractory manifestations of the antiphospholipid syndrome: a multicentre Israeli experience","volume":"39","author":"Agmon-Levin","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.blre.2026.101364_bb0710","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the \u2018CAPS Registry\u2019","volume":"32","author":"Cervera","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2026.101364_bb0715","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2026.101364_bb0720","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1055\/s-0043-1770784","article-title":"The effect of rituximab on antiphospholipid titers in patients with antiphospholipid syndrome","volume":"7","author":"Youkhana","year":"2023","journal-title":"TH Open"},{"key":"10.1016\/j.blre.2026.101364_bb0725","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/ard.2007.078402","article-title":"B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres","volume":"67","author":"Ioannou","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2026.101364_bb0730","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13030741","article-title":"Platelets and Thrombotic Antiphospholipid Syndrome","volume":"13","author":"Tohidi-Esfahani","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2026.101364_bb0735","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.950465","article-title":"Immunomodulatory actions of vitamin D in various immune-related disorders: a comprehensive review","volume":"14","author":"Ghaseminejad-Raeini","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101364_bb0740","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/ard.2010.134817","article-title":"Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression","volume":"70","author":"Agmon-Levin","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2026.101364_bb0745","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/0961203312446386","article-title":"Vitamin D and antiphospholipid syndrome","volume":"21","author":"Andreoli","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.blre.2026.101364_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the \u201cCAPS Registry\u201d","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2026.101364_bb0755","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1186\/s12879-019-4146-5","article-title":"Invasive meningococcal disease in patients with complement deficiencies: a case series (2008\u20132017)","volume":"19","author":"Ladhani","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.blre.2026.101364_bb0760","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101364_bb0765","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In Vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101364_bb0770","article-title":"Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission","volume":"N Y). 6","author":"Wang","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.blre.2026.101364_bb0775","author":"Safety and Efficacy of Universal CD19-targeting CAR-\u03b3\u03b4T Cells in Refractory Autoimmune Diseases"},{"key":"10.1016\/j.blre.2026.101364_bb0780","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.971366","article-title":"Low dose versus standard dose rituximab for the treatment of antiphospholipid syndrome: A pilot study from a tertiary medical center","volume":"13","author":"Gan","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101364_bb0785","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/rheumatology\/ker526","article-title":"B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels","volume":"51","author":"Lazarus","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.blre.2026.101364_bb0790","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/rheumatology\/kez623","article-title":"A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE","volume":"59","author":"van Dam","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.blre.2026.101364_bb0795","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2010-07-299099","article-title":"Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome","volume":"117","author":"Romay-Penabad","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0800","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015345","article-title":"A novel dimeric inhibitor targeting Beta2GPI in Beta2GPI\/antibody complexes implicated in antiphospholipid syndrome","volume":"5","author":"Kolyada","year":"2010","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.blre.2026.101364_bb0805","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood.V120.21.2205.2205","article-title":"Pharmacokinetics, serum stability and immunogenicity of a polypeptide inhibitor of B2GPI\/antibody complexes tested in mice","volume":"120","author":"Porter","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0810","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood-2013-08-520882","article-title":"Inhibition of thrombotic properties of persistent autoimmune anti-\u03b22GPI antibodies in the mouse model of antiphospholipid syndrome","volume":"123","author":"Kolyada","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101364_bb0815","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/jth.13314","article-title":"Soluble analog of ApoER2 targeting beta2-glycoprotein I in immune complexes counteracts hypertension in lupus-prone mice with spontaneous antiphospholipid syndrome","volume":"14","author":"Kolyada","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2026.101364_bb0820","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/febs.13185","article-title":"An A1-A1 mutant with improved binding and inhibition of \u03b22GPI\/antibody complexes in antiphospholipid syndrome","volume":"282","author":"Kolyada","year":"2015","journal-title":"FEBS J"},{"key":"10.1016\/j.blre.2026.101364_bb0825","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/art.43258","article-title":"Antiphospholipid syndrome: an antibody-mediated disease with emerging therapeutic opportunities","volume":"77","author":"Newman","year":"2025","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2026.101364_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102610","article-title":"Can we cure antiphospholipid syndrome?","volume":"96","author":"Meroni","year":"2025","journal-title":"Curr Opin Immunol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:08:07Z","timestamp":1788221287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":168,"alternative-id":["S0268960X26000032"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101364","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting antiphospholipid syndrome: A thrombo-inflammatory disorder beyond clotting","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101364"}}